Nimbus Therapeutics
NEWS
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Lightstone Ventures recently announced the closing of Lightstone Ventures III, securing $375 million to invest in early-stage firms that develop high-impact technologies that can change lives.
Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week’s appointments.
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
The drugs target a protein called STING (stimulator of interferon genes), which plays an important role in the innate immune system, which is the body’s first line of defense against various pathogens.
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
JOBS
IN THE PRESS